Conavi highlights hybrid IVUS-OCT study results

Executive Summary

• Conavi Medical highlighted a peer‑reviewed publication in Cardiovascular Research demonstrating that its hybrid IVUS‑OCT deep‑learning classifier outperforms single‑modality approaches and expert readers in plaque characterization.
• The study, based on 10 cadaveric human hearts, supports the clinical and commercial value of Conavi’s hybrid imaging platform for coronary interventions.
• Concurrently, the company granted stock options to CFO Mark Quick for 1 million common shares at a $0.41 exercise price.

Key Details

• Publication Title: “Deep learning‑based plaque characterization in hybrid IVUS‑OCT images is superior to single‑modality deep learning analysis and human experts: head‑to‑head comparison against histology.”
• Journal & Sponsor: Published in Cardiovascular Research by the European Society of Cardiology.
• Study Design: Analyzed IVUS‑OCT images matched with histological sections from 10 cadaveric human hearts.
• Results: Hybrid IVUS‑OCT deep‑learning classifier achieved superior plaque characterization accuracy versus single‑modality IVUS, single‑modality OCT, and expert human readers.
• Implications: Validates the clinical value proposition of Conavi’s hybrid imaging system for more precise, image‑guided coronary interventions; reinforces commercial potential.
• Key Contributors: Dr. Brian Courtney (co‑inventor of foundational hybrid technology) plus imaging experts from Canada, Europe, the United States, and AI researchers at Queen Mary University of London.
• CEO Quote: Tom Looby emphasized that peer‑reviewed research “reinforces the clinical value proposition behind Conavi's technology platform” and highlights the importance of comprehensive hybrid systems as the field moves toward precise image‑guided interventions.
• Regulatory Update: Conavi has submitted its next‑generation Novasight imaging system to the U.S. FDA for regulatory clearance, continuing preparations for commercialization and clinical adoption.
• Stock Option Grant: CFO Mark Quick received options to purchase 1,000,000 common shares at $0.41 per share (five‑day VWAP on grant date). Options vest per the company’s stock option plan and expire ten years from grant; subject to regulatory approvals.

Notable Quotes

• “Peer‑reviewed academic research continues to reinforce the clinical value proposition behind Conavi's technology platform,” – Tom Looby, CEO.